Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425574 · ClinicalTrials.gov registry record
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
A clinical trial of Stargardt Disease and Stargardt Macular Dystrophy, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT07425574: Recruiting study of Stargardt Disease and Stargardt Macular Dystrophy, sponsored by Astellas Pharma Global Development.
NCT07425574 is a study of Stargardt Disease and Stargardt Macular Dystrophy that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 90 participants, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07425574, a study of Stargardt Disease and Stargardt Macular Dystrophy, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to vision loss in the center of the eye. Side vision (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically happens in childhood, but many people do not develop it until they are adults. As well as STGD, there are other macular dystrophies that look very similar to STGD but that are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies. This is because they look the same clinically and have similar symptoms. Since different genes can cause these conditions, genetic testing is the only way to be sure which specific condition a person has. In this study, researchers want to learn if the disease progresses in a similar way in people with STGD and STGD-like macular dystrophies. People taking part in the study will continue to manage their condition, as agreed with their own doctor. People will visit their clinic every 6 months to have various standard eye tests and imaging. The information collected will include questions about people's wellbeing, general health, medication and supplements taken, and daily activities. Children over 6 years old and adults with STGD-type macular dystrophies may take part in this study. They will be in the study for up to 24 months (2 years). The study sponsor (Astellas) will not decide how people's condition is managed. However, the sponsor will provide instructions on when people visit their clinic and what is recorded during the study. If available, medical records, clinical and imaging data from previous visits going back 24 months will also be reviewed.
Primary Outcome
BCVA will be measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters chart.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2028-07-31 |
What NCT07425574 shows while recruiting
NCT07425574 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target.
The record links to 3 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07425574 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07425574 about?
NCT07425574 is a clinical study titled "A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults". Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads...
What is the current status of trial NCT07425574?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2026-02-20. Estimated completion is 2028-07-31.
What conditions does trial NCT07425574 study?
This clinical trial studies the following conditions: Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy.
What interventions are being tested in trial NCT07425574?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07425574?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07425574 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07425574's enrollment target sits among peer trials
90 4th of 16 higher than 13 of 16 other Stargardt Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI